Trending...
- California: With new laws and 800 new arrests, CHP keeps taking down organized retail theft operations statewide
- Small-Firm Leaders Must Prioritize High-Impact Tasks to Prevent Burnout: New Article in AT
- Ktrowe Digital Asset Center Enhances Risk Management and System Transparency
ANNAPOLIS, Md., Jan. 10, 2025 ~ In an exciting announcement, Alphyn, a clinical-stage dermatology company, revealed that their CEO Neal Koller will be presenting at several investor conferences during the upcoming J.P. Morgan Healthcare Week in San Francisco.
The first conference, Biotech Showcase, will take place on January 13th at 10:45 a.m. at the Hilton San Francisco Union Square. Mr. Koller will then move on to the Redefining Every Stage of Investment (RESI) JPM conference on January 14th at 11 a.m. at the San Francisco Marriott Marquis. He has been selected as a finalist in the RESI Innovators Pitch Challenge.
Later that same day, Mr. Koller will also be speaking at NEXUS 2025 from 3 p.m. to 9 p.m. at the Hanger in South San Francisco. During these presentations, he will provide an overview of Alphyn's corporate developments and discuss their lead product candidate, Zabalafin Hydrogel.
More on The Californer
Zabalafin Hydrogel is currently in development to treat atopic dermatitis (AD), a chronic skin condition that affects millions of people worldwide. It is set to begin Phase 2b clinical trials this year and has shown promising results in treating all aspects of AD - including bacterial causes and exacerbation of the disease, as well as managing symptoms such as itchiness, inflammation, and infection.
Alphyn's second candidate is aimed at treating epidermolysis bullosa, a group of rare and potentially fatal skin diseases. With these innovative Multi-Target Therapeutics®, Alphyn hopes to make significant advancements in the field of dermatology and improve the quality of life for those suffering from these conditions.
Investors and industry professionals alike are eagerly anticipating Mr. Koller's presentations and updates on Alphyn's groundbreaking clinical programs during J.P Morgan Healthcare Week next week in San Francisco.
The first conference, Biotech Showcase, will take place on January 13th at 10:45 a.m. at the Hilton San Francisco Union Square. Mr. Koller will then move on to the Redefining Every Stage of Investment (RESI) JPM conference on January 14th at 11 a.m. at the San Francisco Marriott Marquis. He has been selected as a finalist in the RESI Innovators Pitch Challenge.
Later that same day, Mr. Koller will also be speaking at NEXUS 2025 from 3 p.m. to 9 p.m. at the Hanger in South San Francisco. During these presentations, he will provide an overview of Alphyn's corporate developments and discuss their lead product candidate, Zabalafin Hydrogel.
More on The Californer
- California: Paw and order: four new K-9 teams join CHP to increase public safety statewide
- California: Governor Newsom announces multiple clemency actions
- California: Governor Newsom proclaims Veterans Day
- Governor Newsom fights for Californians' access to food benefits while Trump basically says "THE POOR MUST STARVE!"
- California and Fresno unite to tackle unsheltered homelessness through new cooperative agreement
Zabalafin Hydrogel is currently in development to treat atopic dermatitis (AD), a chronic skin condition that affects millions of people worldwide. It is set to begin Phase 2b clinical trials this year and has shown promising results in treating all aspects of AD - including bacterial causes and exacerbation of the disease, as well as managing symptoms such as itchiness, inflammation, and infection.
Alphyn's second candidate is aimed at treating epidermolysis bullosa, a group of rare and potentially fatal skin diseases. With these innovative Multi-Target Therapeutics®, Alphyn hopes to make significant advancements in the field of dermatology and improve the quality of life for those suffering from these conditions.
Investors and industry professionals alike are eagerly anticipating Mr. Koller's presentations and updates on Alphyn's groundbreaking clinical programs during J.P Morgan Healthcare Week next week in San Francisco.
Filed Under: Business
0 Comments
Latest on The Californer
- Celebrating 20 Years of Orangutan Caring Week
- Grammy-winning Cuban-Canadian artist Alex Cuba releases his 11th studio album, "Indole," today
- Local Lighting Experts Debut AI Christmas Decorator: Upload a Photo, Get Instant Professional Holiday Design-- Completely Free
- Surf Air Mobility (N Y S E: SRFM) Accelerates Regional Air Mobility Revolution with Electra Aero Partnership, Palantir Alliance, and Record Revenue
- Cybersecurity is Fast Becoming a Vital Issue for Protecting Personal Information and Portfolio Wealth
- A Night Under the Northern Lights: A Frozen-Inspired Gala to Benefit Weaver Performing Arts
- 10 Essential Tips for Maximizing Value When Choosing Your Orlando Wedding Venue
- Americans Are Trading Offices for Beaches: How Business Ownership Enables the Ultimate Location Freedom
- Redrosethorns Ltd. Liability Co. Publishes Debut Feminist Poetry & Art, To Be (a Woman)
- Style My Soul Welcomes Curated Article Submissions and Podcast Guests
- House of Buneau Premieres "I Don't Know the Mayor" — A Cinematic Noir in Velvet Realism
- Californians are beginning to see cash on their SNAP cards following major win against the Trump administration
- Ladybug Travel Expands Global Creator Network After One Year at Sea
- California: Governor Newsom announces appointments 11.6.2025
- Long Beach to Host Community Meetings on Proposed Mobile Food Facilities Ordinance
- Introducing Garment Saver's Planet-Friendly Makeup Guard
- Environmental leaders, fire practitioners applaud California's efforts to expand beneficial fire this Fall
- Boston Industrial Solutions' Natron® DC Series Ink Has Had an Upgrade!
- Long Beach Seeks Volunteers for 2026 Homeless Point in Time Count
- Colony Ridge Proudly Supports the All Ears! 2025 Sporting Clays Tournament